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Signaling by TSH through its receptor leads to the
dissociation of trimeric G proteins into G and
G. Gs activates adenylyl cyclase, which in-
creases cAMP levels that induce several effects in
the thyroid cell, including transcription of the so-
dium-iodide symporter (NIS) gene through a mech-
anism involving Pax8 binding to the NIS promoter.
Much less is known about the function of G in
thyroid differentiation, and therefore we studied
their role in TSH signaling. G overexpression
inhibits NIS promoter activation and reduces NIS
protein accumulation in response to TSH and for-
skolin. Conversely, inhibition of G-dependent
pathways increases NIS promoter activity elicited
by TSH but does not modify forskolin-induced ac-
tivation. G dimers are being released from the
Gs subfamily of proteins, because cholera toxin
mimics the effects elicited by TSH, whereas per-
tussis toxin has no effect on NIS promoter activity.
We also found that TSH stimulates Akt phosphor-
ylation in a phosphoinositide 3-kinase (PI3K)-de-
pendent and cAMP-independent manner. This is
mediated by G, because its overexpression or
specific sequestration, respectively, increased or
reduced phosphorylated Akt levels upon TSH stim-
ulation. G sequestration increases NIS protein
levels induced by TSH and Pax8 binding to the NIS
promoter, which is also increased by PI3K inhibi-
tion. This is, at least in part, caused by G-medi-
ated Pax8 exclusion from the nucleus that is atten-
uated when PI3K activity is blocked. These data
unequivocally demonstrate that G released by
TSH action stimulate PI3K, inhibiting NIS gene ex-
pression in a cAMP-independent manner due to a
decrease in Pax8 binding to the NIS promoter. (Mo-
lecular Endocrinology 22: 1183–1199, 2008)
TSH, A HETERODIMERIC GLYCOPROTEIN hor-mone synthesized by pituitary thyrotrophs, is con-
sidered to be the main regulator of thyroid function.
TSH action is initiated by its binding to the G protein-
coupled TSH receptor (TSHR), a seven-transmem-
brane receptor located at the surface of thyrocytes
that regulates thyroid cell proliferation and differenti-
ation (1–3). Thyroid cell differentiation induced by TSH
involves the expression of the different genes required
for thyroid hormone synthesis such as the sodium
iodide symporter (NIS), thyroglobulin (Tg), and thy-
roperoxidase (TPO). The NIS protein mediates iodide
uptake by the thyroid follicular cell, a process that
constitutes the first step in thyroid hormone biosyn-
thesis (4, 5). Iodide is subsequently incorporated by
TPO into the Tg molecule. TSH also controls the func-
tional activity of several transcription factors neces-
sary for the expression of these genes such as Pax8,
TTF1/NKx2.1, and TTF2/FoxE1. Pax8 has been re-
ported to be the main transcription factor regulating
NIS gene expression. Stimulation of NIS gene expres-
sion by TSH requires the binding of Pax8 to an en-
hancer element within the NIS promoter [NIS upstream
enhancer(NUE)] (6). Pax8, together with TTF1, also
regulates Tg and TPO expression (7), although for
these genes, FoxE1 is the main mediator of TSH action
(8, 9).
Activation of the TSHR in thyroid membranes in-
duces the coupling to different G proteins: Gs, Gq/11,
and different subtypes of Gi and Go as well as G12
and G13 (10–12). Stimulation of the TSHR leads to the
dissociation of trimeric G proteins into G and G
subunits that in turn trigger complex signaling cas-
cades. Most of the activities of the TSHR are mediated
through the Gs protein, which activates the adenylyl
cyclase/cAMP cascade (1). The increased intracellular
concentration of cAMP activates protein kinase A
(PKA), which is required for thyroid cell differentiation
and proliferation (13). Other signaling pathways acti-
vated by cAMP include the cAMP-binding GTP-ex-
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change factors (cAMP-GEFs or Epac) that function as
exchange factors for the small GTPases Rap1 (14, 15),
Rap2 (16), and Ras (17). GTP-bound Rap1 can acti-
vate the kinases Raf-1, B-Raf, and c-Raf, leading into
ERK1/2 or p38MAPK pathways. Ras activation by
cAMP-GEF is of particular relevance because Ras can
activate other kinase cascades such as the phospho-
inositide 3-kinase (PI3K)/phosphoinositide-dependent
kinase-1 pathway, and it has been demonstrated that
Ras is required for TSH-induced mitogenesis in thyroid
cells (18). In human and rat thyrocytes, TSH can also
stimulate the Gq/phospholipase C cascade (19), and
in dog and human thyrocytes, TSH also activates Gi,
which partially opposes the stimulation through Gs
and is not related to TSH-mediated proliferation (12).
G has been demonstrated to regulate more than
20 effectors including phospholipases (20), adenylyl
cyclases (21), ion channels (22), G protein-coupled
receptor kinases (23), and PI3Ks (24). G protein-cou-
pled receptors (GPCRs) regulate through  dimers
intracellular signals involved in cell growth and differ-
entiation in different cell types. Through  dimers,
GPCRs can activate the MAPK pathway (25–27) and
the PI3Ks, a family of lipid kinases involved in multiple
biological processes including cell proliferation and
survival, cytoskeletal remodeling, and membrane traf-
ficking (28). In thyrocytes, PI3K has a central role in
controlling both cell proliferation and differentiation.
PI3K is activated in thyrocytes by many growth factors
such as insulin/IGF-I, hepatocyte growth factor (HGF),
or epidermal growth factor (EGF) (29). Treatment with
PI3K inhibitors or the expression of a dominant-neg-
ative form of PI3K causes a G1 arrest of rat thyroid
cells stimulated to proliferate with TSH (30, 31), and it
has been reported that PI3K is required for thyrocytes
to proliferate upon TSH stimulation (32). Concerning
differentiation of thyroid cells, we have reported that
activation of PI3K by IGF-I inhibits the expression of
the NIS stimulated by TSH/cAMP (33). In thyroid cells,
the role of G subunits in the transmission of intra-
cellular signals induced by GPCRs remains essentially
unknown. This, together with the fact that not all the
actions of TSH/TSHR can be explained by cAMP in-
crements, led us to study the involvement of G
dimers in TSH-dependent signaling and the regulation
of gene expression in thyroid cells. We have found that
TSH activates a cAMP-independent signaling cascade
that increases PI3K activity and regulates NIS gene
expression.
RESULTS
Overexpression of G Dimers Inhibits NIS
Transcription
Upon TSH binding to its cell surface GPCR, G proteins
dissociate into G and G subunits. It is well known
that the stimulatory G subunit (Gs) activates adeny-
lyl cyclase, leading to an increase in cAMP levels that
in turn induce several actions in the thyroid cell, in-
cluding stimulation of NIS gene expression. The role of
the G subunits released by TSH is not known, but
one of the putative effectors of G, the lipid kinase
PI3K, has been found by our group to decrease NIS
gene expression (33). To initiate the study of G
function in the thyroid cell, we analyzed the effect of 
dimers on NIS transcription stimulated by TSH or for-
skolin, an activator of adenylyl cyclase that increases
cAMP levels. For this purpose, PCCl3 cells were trans-
fected with the reporter vector pNIS-2.8 carrying lu-
ciferase driven by the NIS promoter and increasing
amounts of the expression vectors for G1 and G2
subunits, FLAG-G1 and HA-G2. After transfection,
cells were maintained for 3 d in starvation medium and
then left untreated or treated for another 24 h with TSH
or forskolin. Figure 1A shows that overexpression of
G dimers significantly reduces NIS promoter activity
stimulated by TSH and forskolin in a dose-dependent
manner, indicating that G signaling interferes with
cAMP induction of NIS gene transcription. Immuno-
detection of one of the tagged components of the 
dimer, the FLAG-1 protein, is shown. Due to the
unspecificity of hemagglutinin (HA) antibodies, the ex-
pression of HA-2 was demonstrated by RT-PCR us-
ing RNA preparations from an experiment performed
under the same conditions (data not shown). We also
wanted to study whether G could regulate endog-
enous NIS gene expression in PCCl3 cells. For this
purpose, PCCl3 cells were transfected either with 5 g
each of FLAG-1 and HA-2 or with the same amount
of the control vector pcDNA3.1. After 5 d in starvation
medium, cells were left untreated or treated with TSH
or forskolin for 24 h and then harvested for Western
blot analysis of NIS protein levels. The results are
shown in Fig. 1B. NIS protein expression induced by
TSH or forskolin is clearly less in cells overexpressing
G dimers, compared with cells transfected with the
control vector. NIS expression levels were quantified
with respect to actin expression from three indepen-
dent experiments; these normalized levels are graph-
ically shown below a representative Western blot and
indicate that the overexpression of G dimers signif-
icantly decreases NIS protein levels induced by TSH
(P  0.01) and forskolin (P  0.001).
It should be noted that due to the long half-life of the
NIS protein (34), cells must be kept in starvation me-
dium for at least 5 d. Because TSH elicits survival
signals in the cell and a prolonged deprivation of the
hormone could render the cells apoptotic, we per-
formed a cell cycle profile (data not shown) of cells
maintained in starvation medium for up to 6 d to con-
firm that the results obtained are not due to a high rate
of apoptotic cells under the conditions used in these
experiments. The data obtained indicate that the per-
centage of apoptotic cells deprived of TSH for 6 d
(sub-G1  2.91%) is similar to that of cells growing in
control medium containing TSH and serum (sub-G1 
0.20%). These data confirm that the experimental ap-
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proach is reliable and that apoptosis does not appre-
ciably affect the results obtained.
TSH Induces the Release of G Dimers that
Inhibit NIS But Not Tg Expression
Next we wanted to study whether endogenous G
dimers released in response to TSH could also regu-
late NIS transcription. To this end, we inhibited G
signaling by using two different G scavengers, CD8-
ARK and pCISGT-1 (GT). CD8-ARK is a chimeric
molecule containing the extracellular and transmem-
brane domains of CD8 fused to the carboxyl-terminal
domain of -adrenergic kinase (ARK), which includes
the high-affinity -binding region of the kinase and
thus acts as a G scavenger (35). The ARK peptide
specifically inhibits G signaling and is a useful tool
to distinguish between G- and G-dependent path-
ways (36). GT is a vector that expresses the G protein
-subunit of transducin, which also acts as a  scav-
enger. We discard the possibility of using RNA inter-
ference to deplete G and G subunits expression
because it has been reported that complete loss of
expression of G dimers also abolishes G-mediated
pathways (37). Furthermore, the G and G isoforms
expressed in the thyroid and the specific forms re-
leased by TSH binding to its receptor are currently
unknown. Expression of CD8-ARK produced a dose-
Fig. 1. Regulation of NIS Gene Expression by G12
A, PCCl3 cells were transfected with 5 g pNIS-2.8, 0.5 g pRL-TK, and 0, 1, 3, or 5 g each of FLAG-G1 and HA-G2 and
control vector pcDNA3.1 to keep the total amount of transfected DNA constant. After transfection, cells were maintained for 48 h
in starvation medium and then left untreated () or treated with TSH or forskolin (Forsk) for 24 h. Cells were then harvested for
luciferase and Renilla activity determinations. Relative luciferase activity is the value of light units normalized to Renilla activity
derived from transfected pRL-TK to correct for transfection efficiency. NIS promoter activity is expressed as the fold induction
over the basal levels (equal to 1) of untreated cells not transfected with FLAG-G1 and HA-G2. The data represent the mean 
SD (n  3) of one experiment, which is representative of at least three independent experiments. Statistical significance was
evaluated by a two-tailed t test. Differences vs. cells not transfected with FLAG-G1 and HA-G2 under the same treatment were
considered significant at P 0.05; *, P 0.05; **, P 0.01–0.001. The same protein extracts were used for detection by Western
blot analysis of FLAG-G1 and actin shown below. B, PCCl3 cells transfected with 10 g of pcDNA3.1 or 5 g each of FLAG-1
and HA-2 expression vectors. After transfection, cells were maintained for 5 d in starvation medium and were then left untreated
() or treated with TSH or forskolin for 24 h. Cells were then harvested and total protein extracted for immunoblotting with anti-NIS
antibody. Anti-Flag antibody was used to control transfection efficiency and anti-actin antibody as a loading control. The panel
shows a representative Western blot, and the graphic below is the quantification of NIS protein levels normalized to the loading
control. NIS relative protein levels are expressed as the fold induction over the basal levels (equal to 1) of untreated starved cells
(). Values represent the average of three different experiments SD. Statistical significance was evaluated by a two-tailed t test.
Differences vs. cells transfected with the control vector under the same treatment were considered significant at P 0.05; **, P
0.01–0.001; ***, P  0.001.
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dependent increase in the stimulation of NIS transcrip-
tion by TSH; however, CD8-ARK expression did not
produce any significant change in the stimulation by
forskolin (Fig. 2A, left and middle panels). The same
results were obtained when GT was transfected and
cells were treated with TSH (Fig. 2A, right panel) or
forskolin (not shown). These findings indicate that G
subunits released after TSH treatment inhibit NIS tran-
scription. As expected, this effect was not observed
when cells were treated with forskolin, which directly
activates adenylyl cyclase and cAMP production but
does not induce G release. Although it does not
affect the interpretation of the results, it is interesting
to note that we observe an increase in CD8-ARK
expression levels when the cells are stimulated with
TSH or forskolin; this is possibly due to the differences
between the expression machinery of quiescent and
active cells (38) (Fig. 2A, lower panels). Because it has
been reported that the TSHR is able to couple to
members of the four G protein families, it is interesting
to determine from which G protein subtype the G
dimers that decrease NIS expression are being re-
leased. TSH transmits its signal into the cell mainly
through Gs proteins (1), but it has been reported that
high nonphysiological doses of TSH can activate the
Gq/phospholipase C pathway in rat (39) and human
thyroid (40) cells. Despite this high concentration of
hormone, the activation of this pathway is always very
weak (1, 39). Because we are using hormone concen-
trations at physiological levels, the Gq family of pro-
teins can be ruled out as a potential G donor in our
experiments.
Coupling of the TSHR to Gi proteins has also been
reported (11). Inhibition of Gi signaling using pertussis
toxin (PTX) increases cAMP accumulation in response
to TSH in human thyroid slices (10) but not in rat PCCl3
(41) or FRTL-5 (42) cells.
Fig. 2. Effects of G Sequestration and PTX or CTX Treatment on NIS Gene Expression
A, PCCl3 cells were transfected with 5 g pNIS-2.8, 0.5 g pRL-TK, and 0, 1, 3, or 5 g CD8-ARK or pCISGT1 and control
vector CD8 to keep the total amount of transfected DNA constant. After transfection, cells were maintained for 48 h in starvation
medium and left untreated () or treated with TSH or forskolin (Forsk) for 24 h. Cells were then harvested for luciferase and Renilla
activity assays; NIS promoter activity was determined as described in the legend of Fig. 1A. Statistical significance was evaluated
by a two-tailed t test. Differences vs. cells transfected with the control vector under the same treatment were considered
significant at P  0.05, ns, not significant (P  0.05); **, P  0.01–0.001; ***, P  0.001. The same protein extracts were used
for Western blot detection of CD8-ARK and actin shown below. B, PCCl3 cells were transfected with 5 g pNIS-2.8, 0.5 g
pRL-TK (both panels), and 5 g CD8-ARK or CD8 control vector (right panel). After transfection, cells were maintained for 48 h
in starvation medium and treated with TSH or CTX (right panel) for 24 h. PTX was added 24 h before TSH treatment (left panel).
Cells were then harvested for luciferase and Renilla activity assays; NIS promoter activity was determined as described in the
legend of Fig. 1A. Statistical significance was evaluated by a two-tailed t test. Differences vs. cells in the absence of PTX (left
panel) or vs. cells transfected with the control vector under the same treatment (right panel) were considered significant at P 
0.05; ns, not significant (P  0.05); **, P  0.01–0.001; ***, P  0.001.
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If G dimers released in response to TSH are com-
ing from the activation of Gi, there should be an in-
crease in the activity of the NIS promoter when Gi
coupling to the TSHR is blocked using PTX. We show
in Fig. 2B, left panel, that TSH promotes an increase in
the activity of the NIS promoter, but there is no further
significant increase when the cells are stimulated in
the presence of PTX. These data indicate that, at least
in these cells, TSH is not promoting the activation of Gi
proteins at the concentrations used.
We have also performed an experiment using chol-
era toxin (CTX) as a source of G dimers specifically
released from Gs proteins. Treatment of PCCl3 cells
with CTX elicits an increase in the activity of the NIS
promoter to a similar extent as TSH. Moreover, CTX
treatment of PCCl3 cells transfected with ARK pro-
motes a further and significant increase (P  0.01–
0.001) in the activity of the NIS promoter in the same
way as in cells stimulated with TSH (Fig. 2B, right
panel). Together, these results show that G dimers
that decrease NIS promoter activation in response to
TSH are released upon Gs protein activation.
To analyze how G sequestration influences en-
dogenous NIS protein expression, PCCl3 cells were
transfected with CD8-ARK or a vector carrying CD8
only. After 5 d in starvation medium, cells were left
untreated or treated with TSH or forskolin for 24 h and
then harvested for Western blot analysis. Figure 3A
shows that induction of NIS protein levels by TSH in
cells expressing CD8-ARK is significantly (P  0.01–
0.001) higher than in cells treated with the control CD8
vector. This difference was not found when cells were
treated with forskolin; i.e. NIS protein levels were sim-
ilar in cells transfected with CD8-ARK and with the
CD8-vector. Different results were obtained when Tg
protein levels were analyzed. Tg protein expression
was induced by TSH and forskolin to the same extent,
and both effects were not significantly altered by CD8-
ARK transfection. The induction levels were quanti-
fied with respect to actin or Sp1 expression and are
shown below a representative Western blot. We also
analyzed the activity of the Tg promoter in cells ex-
pressing CD8-ARK. The results shown in Fig. 3B
indicate that G subunits released by TSH do not
significantly inhibit Tg transcription.
Thus, G dimers released in response to TSH in-
hibit NIS gene expression but do not interfere with Tg
expression, demonstrating that signaling pathways
Fig. 3. G Effect on NIS and Tg Endogenous Protein Levels
A, PCCl3 cells were transfected with 5 g control CD8 vector or CD8-ARK. Transfected cells were maintained for 5 d in
starvation medium and were then left untreated () or treated with TSH or forskolin for 24 h. Cells were then harvested and total
protein extracted for Western blotting with anti-NIS and anti-Tg antibodies. The immunoblot with anti-CD8 shows CD8-ARK
expression and was used to control transfection efficiency. Membranes were hybridized with anti-actin or anti-Sp1 antibodies as
loading controls. The panels show a representative Western blot and the graphics below show the quantification of NIS or Tg
protein levels normalized to the respective loading control. Relative NIS and Tg protein levels are expressed as the fold induction
over the basal levels (equal to 1) of untreated, CD8-transfected cells (). Values represent the average of three different
experiments  SD. Statistical significance was evaluated by a two-tailed t test. Differences vs. cells transfected with the control
vector under the same treatment were considered significant at P  0.05; ns, not significant (P  0.05); **, P  0.01–0.001. B,
PCCl3 cells were transfected with 3 g hTGenh/prm-Luc, 0.5 g pRL-TK, and 5 g CD8-ARK or CD8. After transfection, cells
were maintained for 48 h in starvation medium and were then left untreated or treated with TSH for 24 h. Cells were then harvested
for luciferase and Renilla activity assays, and Tg promoter activity was determined as described for NIS promoter activity in the
legend of Fig. 1A. Statistical significance was evaluated by a two-tailed t test. Differences between TSH-treated CD8-ARK
transfected cells and TSH-treated cells transfected with the control vector were not significant (ns, P  0.05).
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downstream from G differentially regulate thyroid
gene expression. This effect was not due to variations
in cAMP levels, because overexpression or seques-
tration of G dimers did not have any apparent effect
on the fold induction of cAMP in response to TSH (Fig.
4A). The absence of apparent changes in cAMP in-
duction levels was also demonstrated transfecting
PCCl3 cells with a luciferase reporter construct con-
taining three cAMP response elements (CRE) in tan-
dem (Fig. 4B).
TSH Induces Akt Phosphorylation through PI3K
PI3K has been reported to be one of the main targets
of G signaling initiated by GPCRs. Because we
found in a previous study that PI3K down-regulates
NIS gene expression (33), we decided to study
whether PI3K is an effector of G subunits in thyroid
cells, able to inhibit NIS expression. First of all, we
analyzed PI3K activation by TSH, forskolin, and IGF-I
in PCCl3 cells. To this end, we analyzed by Western
blot the phosphorylation level of the PI3K target Akt.
Figure 5A shows that TSH induces Akt phosphoryla-
tion in a time-dependent manner, with a maximum
stimulation between 30 min and 1 h. Forskolin also
increased phosphorylated Akt (pAkt) levels although to
a lesser extent than TSH. pAkt levels after 15 min of
IGF-I treatment are shown as a positive control and
indicate that Akt phosphorylation in response to TSH,
although clearly detectable, is not as high as the
strong signal elicited by IGF-I. Induction of Akt phos-
phorylation by either TSH or forskolin, at short times
(30 min) or for a longer period of 24 h, was inhibited by
LY294002 (LY) (Fig. 5B), indicating that PI3K is medi-
ating Akt phosphorylation in response to TSH and
forskolin. Total Akt levels were not altered among the
different experimental conditions, indicating that
changes in the phosphorylation status of Akt are not
due to an increase in total Akt protein.
It has been suggested that some of the effects
observed in thyroid cells in response to TSH, such
as PI3K/Akt activation, could be due to growth fac-
tor contamination of the TSH preparation. Experi-
ments shown up to now in the present study were
performed using bovine pituitary TSH. To rule out
the possibility of growth factor contamination, we
analyzed the effect of human recombinant TSH
(hrTSH) both on NIS transcription (Fig. 5C) and on
Akt phosphorylation (Fig. 5D). NIS promoter activity
was similar in cells treated with hrTSH and in cells
treated with bovine TSH. In addition, hrTSH also
stimulates Akt phosphorylation in a time-dependent
manner. We confirmed that the increase in pAkt
levels induced by hrTSH is due to PI3K activation
using two different PI3K inhibitors: LY294002 (LY),
at concentrations ranging from 1–20 M, and wort-
mannin (Wort), at concentrations from 25–100 nM.
Western blot analyses of pAkt and total Akt levels
are shown in Fig. 5E.
Fig. 4. Effect of G on TSH-Induced cAMP Production
A, PCCl3 cells were transfected with 5 g pcDNA3.1, 3 or
5 g CD8-ARK, or 3 g of both FLAG-G1 and HA-G2
expression vectors. Transfected cells were maintained for
48 h in starvation medium and treated with 0.5 mM IBMX for
30 min, followed by 1 nM TSH treatment for 1 h. Cells were
then harvested for determination of cAMP levels. cAMP in-
duction in response to TSH is shown as the fold induction
over basal levels (equal to 1) of starved cells (). The data
represent the mean  SD (n  3) of one experiment, which is
representative of three independent experiments. Statistical
significance was evaluated by a two-tailed t test. Differences
of TSH-treated, expression vector-transfected cells vs. cells
transfected with the control vector and treated with TSH were
not significant (ns, P 0.05). B, PCCl3 cells were transfected
with 5 g 3XCRE-LUC reporter, 0.5 g pRL-TK, 5 g
pcDNA3.1, and 3 or 5 g CD8-ARK or 5 g of both FLAG-
G1 and HA-G2 expression vectors. After transfection, cells
were maintained for 48 h in starvation medium and were then
left untreated or treated with TSH for 24 h. Cells were then
harvested for luciferase and Renilla activity assays. Relative
luciferase activity is the value of light units normalized to
Renilla activity derived from transfected pRL-TK to correct for
transfection efficiency. 3XCRE-LUC activity is expressed as
the fold induction over basal levels (equal to 1) of starved cells
(). The data represent the mean  SD (n  3) of one exper-
iment, which is representative of three independent experi-
ments. Statistical significance was evaluated by a two-tailed
t test. Differences vs. cells transfected with the control vector
were not significant (ns, P  0.05).
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In view of these results, it can be concluded that
TSH stimulates Akt phosphorylation in PCCl3 cells
through PI3K activation.
TSH Induces Akt Phosphorylation in a cAMP-
Independent Manner
Stimulation of PI3K by TSH in thyroid cells and the
involvement of cAMP in this signaling pathway are
controversial. The results reported up to date show
that PI3K activation by TSH depends on the thyroid
cell type studied. When this pathway is active, it has
been suggested that cAMP is mediating the stimula-
tion of PI3K by TSH. In the present study, we wanted
to analyze whether cAMP is mediating the signal ini-
tiated by TSH to activate PI3K in PCCl3 cells. For this
purpose, we used two different inhibitors that act at
different levels in the cAMP signaling pathway. The
first one, H89, inhibits the activity of PKA, one of the
most important targets of cAMP. We have analyzed
the effect of H89 on the phosphorylation of Akt by TSH
in PCCl3 cells. The results are shown in Fig. 6A. Pre-
treatment with H89 increases basal pAkt levels as
reported (43) and does not significantly affect TSH and
forskolin stimulation of Akt phosphorylation. The in-
duction levels were quantified with respect to total Akt
expression and are shown below a representative
Western blot.
The second inhibitor used was adenosine 3,5-
cyclic monophosphorothioate, Rp-isomer, triethylammo-
Fig. 5. Activation of the PI3K/Akt Pathway by TSH, Forskolin, and IGF-I Treatment
PCCl3 cells were maintained for 48 h in starvation medium and then treated with bovine TSH (A–C), forskolin (Forsk) (A and
B), or hrTSH (C–E) for the periods of time indicated or with IGF-I for 15 min (A). The PI3K inhibitors LY294002 (LY) (B and E) or
wortmannin (Wort) (E) were added at the indicated final concentrations 1 h before the different treatments. After treatment, cells
were harvested for total protein preparation and pAkt detection by Western blot. As a loading control, membranes were hybridized
with anti-total Akt antibodies. Western blots representative of at least three independent experiments are shown. C, PCCl3 cells
were transfected with 5 g pNIS-2.8 and 0.5 g pRL-TK. After transfection, cells were maintained for 48 h in starvation medium
and were then left untreated or treated with 1 nM bovine TSH (bTSH) or hrTSH at the concentrations indicated for 24 h. Cells were
then harvested for luciferase and Renilla activity determinations. NIS promoter activity is expressed as the fold induction over
basal levels (equal to 1) of untreated cells (), and calculated as explained in the legend of Fig. 1. The data represent the mean
 SD (n  3) of one experiment, representative of at least three independent experiments.
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nium salt (Rp-cAMP), a specific competitor of cAMP
for its binding site that avoids cAMP activation of the
different cAMP targets, including PKA. Cells were
treated with 10 and 30 M Rp-cAMP and then treated
with TSH for 30 min. The presence of Rp-cAMP does
not prevent stimulation of Akt phosphorylation by
hrTSH at the different concentrations used (Fig. 6B).
To demonstrate that Rp-cAMP is active in these con-
ditions, we analyzed the phosphorylation state of
CRE-binding protein (CREB), a transcription factor
that is phosphorylated in response to cAMP increases.
The results show that both TSH- and forskolin-in-
duced CREB phosphorylation is strongly diminished in
the presence of 30 M Rp-cAMP (Fig. 6, B and C,
respectively), indicating that Rp-cAMP at this concen-
tration is inhibiting cAMP signaling. Taken together,
these results demonstrate that cAMP does not com-
pletely mediate TSH-dependent stimulation of Akt
phosphorylation in PCCl3 cells.
G Subunits Released by TSH Action Stimulate
Akt Phosphorylation
The results reported above indicate that TSH can ac-
tivate the PI3K pathway in a cAMP-independent man-
ner. In view of these findings, the question arises
whether PI3K is an effector of G dimers released by
the action of TSH in PCCl3 cells. To answer that ques-
tion, we analyzed the effect of  overexpression or
sequestration on pAkt levels induced by TSH, forsko-
lin, or IGF-I. Figure 7A shows that overexpression of
 subunits induces phosphorylation of Akt. On the
other hand, transfection of CD8-ARK inhibits Akt
phosphorylation induced by TSH (Fig. 7B). As ex-
pected, this effect was not observed in cells treated
with forskolin or after treatment with IGF-I, a growth
factor that mediates PI3K/Akt activation through its
binding to tyrosine kinase receptors not coupled to G
proteins (Fig. 7B). In conclusion, these results indicate
that TSH can stimulate Akt phosphorylation through
the release of G dimers.
G Release Induced by TSH Reduces Pax8
Binding to the NIS Promoter
Our data clearly show that G dimers repress NIS
promoter activity, and therefore, we explored the
mechanism involved in this inhibition. We focused our
attention on the transcription factor Pax8 because it is
the main mediator of NIS transcription (6). First we
determined Pax8 protein levels in PCCl3 cells trans-
fected with the CD8 expression vector, as a control, or
with the CD8-ARK expression vector. As shown in
Fig. 8A, TSH (P  0.01–0.001) and forskolin (P 
0.001) treatment significantly increased Pax8 protein
levels compared with untreated cells. Sequestration of
G dimers by expression of CD8-ARK did not sig-
Fig. 6. Role of cAMP and PKA in TSH- and Forskolin-Induced Akt Phosphorylation
PCCl3 cells were maintained for 72 h in starvation medium and then left untreated or treated with TSH or forskolin (Forsk) for
30 min. A, The PKA inhibitor H89 was added at 10 M 1 h before TSH or forskolin treatment. The panel shows a representative
Western blot, and the graphic below shows the quantification of pAkt protein levels normalized to Akt1/2 protein levels. The pAkt
relative protein levels are expressed as the fold induction over basal levels (equal to 1) of starved cells (). Values represent the
average of three different experiments  SD. Statistical significance was evaluated by a two-tailed t test. Differences between
similarly treated cells in the absence or presence of H89 were considered significant at P  0.05; ns, not significant (P  0.05);
*, P  0.05. B, Different concentrations of the cAMP competitor Rp-cAMP were added 1 h before hrTSH treatment for 30 min.
C, Rp-cAMP (30 M) was added 1 h before treatment with 1 M forskolin for 30 min. The immunoblots were probed with anti-pAkt,
Akt1/2, pCREB, and CREB1 as indicated.
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nificantly affect Pax8 protein levels compared with the
cells transfected with the control vector.
Because G dimer sequestration did not modify
Pax8 protein levels, we determined whether under
these conditions Pax8 binding to its site within the
NUE in response to TSH or forskolin is changed. To
this end, PCCl3 cells were transfected with the CD8 or
the CD8-ARK expression vectors, maintained for 3 d
in starvation medium, and were then left untreated or
treated for 24 h with TSH or forskolin. Nuclear extracts
were obtained, and Pax8 binding to its site in the NIS
promoter was determined by EMSA. The results show
that in the control CD8 cells, the Pax8/DNA complex
increases in response to both TSH (Fig. 8B, compare
lanes 2 and 3) and forskolin (Fig. 8C, compare lanes 2
and 3). Interestingly, when G dimers were seques-
tered by ARK expression, an increase in the Pax8/
DNA complex was observed only in cells treated with
TSH (Fig. 8B, compare lanes 3 and 8) but not with
forskolin (Fig. 8C, compare lanes 3 and 8). The same
results were obtained when PI3K was inhibited by
treatment of control CD8 cells with LY294002 (LY);
thus, we see an increase in the Pax8/DNA complex in
response to TSH (Fig. 8B, compare lane 3 with 12) but
no modification in response to forskolin (Fig. 8C, com-
pare lane 3 with 12). In all cases, the specificity of the
complex formation was determined by competition
with related (Fig. 8, B and C, lanes 4, 9, and 13) or
unrelated (Fig. 8, B and C, lanes 5, 10, and 14) oligo-
nucleotides. The complex was also competed with an
anti-Pax8 antibody generated against the Pax8 DNA-
binding site (Fig. 8, B and C, lanes 6), demonstrating
that Pax8 protein forms part of the complex. These
data clearly demonstrate that the molecular mecha-
nism involved in NIS repression by G dimers takes
place at the transcriptional level, affecting Pax8 bind-
ing to the NUE. This effect occurs only when cells are
treated with TSH but not with forskolin, which does not
induce G release, and is reverted when PI3K is
inhibited. This confirms that G dimers released
upon TSH binding to its receptor are mediating a de-
crease of Pax8 binding to the NIS promoter that is
transmitted by the PI3K pathway.
The effect of G dimers on Pax8 localization was
studied by immunofluorescence (Fig. 9). In cells cul-
tured in the absence of TSH for 2 d, Pax8 is barely
expressed. When these cells are treated with TSH for
24 h, Pax8 expression is increased and is predomi-
nantly located in the nucleus and not observed in the
cytoplasm. The transfection with G1 and G2 sub-
units expression vectors induces a significative exclu-
sion of Pax8 from the nucleus to the cytoplasm, an
effect that was impaired by LY294002 pretreatment.
G sequestration by ARK transfection retains Pax8
into the nucleus.
DISCUSSION
In the present study, we demonstrate a role for G
dimers in TSH-dependent signaling in thyroid cells.
G dimers released after TSH treatment lead to PI3K/
Akt activation and regulate NIS gene expression in
PCCl3 cells. In a previous study (33), we reported an
increase of TSH-dependent induction of NIS gene ex-
pression in the presence of the PI3K inhibitor
LY294002. Those results suggested the existence of a
pathway from TSH to PI3K that inhibits NIS gene ex-
pression. Here, we confirm this suggestion specifically
Fig. 7. G Effect on Akt Phosphorylation
PCCl3 cells were transfected with 5 g each of FLAG-G1 and HA-G2 or with 10 g pcDNA3.1 (A) or with 5 g CD8-ARK
or CD8 control vector (B). After transfection, cells were maintained for 48 h in starvation medium and were then left untreated or
treated with TSH or forskolin (Forsk) for 30 min (A and B) or with IGF-I for 15 min (B). Cells were then harvested for total protein
extraction and pAkt detection by Western blot. Membranes were hybridized with anti-FLAG (A) or anti-CD8 (B) antibodies to show
FLAG-G1 and CD8-ARK expression, respectively. Anti-Akt1/2 detection was used as a loading control. Western blots
representative of at least three independent experiments are shown.
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impairing G dimers signaling by using two different
G scavengers, CD8-ARK and GT. Expression of
these molecules results in a further activation of the
NIS promoter elicited by TSH demonstrating unequiv-
ocally a role of G.
Most of our study has been performed with the spe-
cific scavenger CD8-ARK, a construct that expresses a
chimeric protein containing not only the C-terminal do-
main of the ARK1 protein, where the G binding do-
main is located but also the extracellular and transmem-
brane domains of the CD8 protein that is targeted to the
membrane where it is able to interact with and sequester
G dimers, making it an effective and specific scaven-
ger (35). It has been clearly established that the C-termi-
nal ARK peptide discriminates between G- and G-
mediated pathways (35, 36, 44, 45). The specificity of the
GT as a G scavenger has also been previously tested
(44–48).
Fig. 8. Regulation of Pax8 Binding to Its Element within the NUE
A, PCCl3 cells were transfected with 5 g CD8 or CD8-ARK expression vectors, maintained for 3 d in starvation medium, and
then left untreated or treated with TSH or forskolin (Forsk) for 24 h. Cells were then harvested and total protein extracted for
Western blotting with Pax8 antibody. The immunoblot with anti-CD8 shows CD8-ARK protein levels as a control for transfection
efficiency. Membranes were hybridized with anti-actin antibody as a loading control. The panel shows a representative Western
blot, and the graphic to the right shows the quantification of Pax8 protein levels normalized to the loading control. Relative Pax8
protein levels are expressed as the fold induction over the basal levels (equal to 1) of starved cells transfected with the CD8
expression vector (). Values represent the average of three different experiments  SD. Statistical significance was evaluated
by a two-tailed t test. Both in CD8-transfected cells and in CD8-ARK-transfected cells, TSH and forskolin significantly increase
Pax8 protein levels with respect to untreated cells; **, P  0.01–0.001; ***, P  0.001, respectively, only indicated for
CD8-transfected cells. Differences between CD8-ARK-transfected cells and cells transfected with the control vector under the
same treatment were not significant (ns, P  0.05). B and C, Nuclear extracts from PCCL3 cells transfected and treated as
described in A in the presence or absence of 10 M LY294002 (LY) were obtained for EMSAs with 32P-labeled oligonucleotides
corresponding to the Pax8-binding site (site PB) derived from the NIS Upstream Enhancer (6). The probe was incubated without
(lane 1) or with 7 g nuclear extracts (lanes 2–14) from cells treated as described above and as indicated in the figures.
Competition was performed with a 100-fold molar excess of unlabeled related (Oligo R; lanes 4, 9, and 13) or unrelated (Oligo NR;
lanes 5, 10, and 14) oligonucleotides as well as with an anti-Pax8 antibody (-Pax8; lane 6).
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This effect is not observed in cells treated with the
adenylyl cyclase activator forskolin, indicating that the
G dimers coupled to the TSHR are activating sig-
naling pathways leading to NIS gene repression. Al-
though overexpressed G could bind to Gs, thereby
inactivating it and decreasing cAMP levels, we believe
that the effects observed are not due to a decrease in
cAMP because this inhibitory effect was also observed
in forskolin-treated cells; forskolin acts downstream of
Gs and directly activates adenylyl cyclase. Thus, in-
activation of Gs subunits by G overexpression
should not interfere with forskolin induction of cAMP
elevation. In addition, the induction levels of cAMP in
response to TSH are the same in cells overexpressing
G as in cells expressing the scavenger ARK. Thus,
we can conclude that G inhibition of TSH-induced
NIS transcription is due to a direct action of G and
not to decreased cAMP levels.
Although much work has been done to study the
signaling pathways involved in thyroid cell prolifera-
tion, little is known concerning signaling cascades that
regulate thyroid cell differentiation other than the
cAMP/PKA pathway. Other factors such as insulin/
IGF-I have been reported to increase TSH stimulation
of Tg, TPO, and TSHR expression (49–51), but as we
reported recently, NIS gene expression is inhibited by
insulin/IGF-I, and this effect is mediated in part by
PI3K (33). Thus, PI3K appears to regulate Tg and NIS
gene expression in different ways.
G dimers have been reported to regulate a large
number of effectors, including PI3Ks (24). PI3Ks con-
stitute a large family of lipid kinases that have been
divided into three classes. They phosphorylate the D3
position of the inositol ring of phosphoinositides, gen-
erating phospholipids that are involved in cellular func-
tions including chemotaxis, differentiation, glucose
homeostasis, proliferation, survival, and trafficking (28,
52). These lipid kinases are under tight control of cell
surface receptors, including receptor tyrosine kinases
and GPCRs (53). The most studied PI3Ks are those
belonging to class I. Class IA enzymes consist of a
p110 catalytic subunit complexed to a regulatory sub-
unit, p85, and signal downstream of tyrosine kinases
and Ras, although an activation of p110 by GPCRs
through G dimers has been reported (54). Class IB
PI3K consists of the p110 catalytic subunit com-
plexed to the p101 regulatory subunit and signals
downstream of GPCRs and Ras. GPCRs activate
PI3K and PI3K through direct interaction with G.
The results we present here indicate that TSH can
activate the PI3K/Akt pathway through G dimers
and that this pathway is interfering with the activation
of NIS gene expression in thyroid cells by cAMP. In the
thyroid cell, PI3K plays a critical role in controlling cell
proliferation (30, 31). Several growth factors have been
shown to activate the PI3K pathway (29), and inhibition
of PI3K activity leads to a G0/G1 arrest of thyroid cells
(30, 31). Depending on the cell type, opposing results
have been reported concerning the activation of PI3K/
Akt pathway by TSH (29). It has been suggested that
PI3K/Akt activation by TSH could be due to contam-
inants of the TSH preparation. To address this ques-
tion we used hrTSH and we observed that hrTSH
induces Akt phosphorylation in a PI3K-dependent
manner. In addition, Akt phosphorylation induced by
TSH was abolished when cells were incubated in the
presence of an anti-TSHR antibody (data not shown).
Taken together, these data unequivocally demonstrate
that TSH increases Akt phosphorylation at 10–15 min,
Fig. 9. G Effect on Pax8 Localization
Top panel, Representative immunofluorescence assay.
PCCl3 cells were seeded on coverslips and transfected with
10 g pCDNA3.1, 5 g each of FLAG-1 and HA-2, or 5 g
CD8-ARK. After 48 h in starvation medium, cells were left
untreated or treated with TSH for 24 h. LY294002 (LY) inhib-
itor was added 1 h before TSH addition. After treatment, cells
were fixed, blocked, and incubated with Pax8 and FLAG or
CD8 antibodies followed by Alexa 488 and TexasRed 546
secondary antibodies immunostaining. Cells were then
mounted on Vectashield containing DAPI and observed un-
der a confocal microscope using a 63 magnification objec-
tive. DAPI, Pax8, FLAG, CD8, and the merged pictures are
shown. A representative group of cells from three indepen-
dent experiments is presented. A 0- to 50-m scale is shown
in the first picture of the third column. Bottom panel, Quan-
titative analysis (%) of successfully transfected cells that
present a consistent Pax8 cytoplasmic localization. Five dif-
ferent fields were randomly chosen from each experiment.
The data are the mean  SD of three independent experi-
ments.
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reaching its maximal effect at 30–60 min. At earlier
time points, almost undetectable changes can be ob-
served in our experimental conditions (data not
shown), which considerably differ from those used by
Lou et al. (55). These authors observed a decrease in
Akt phosphorylation after TSH treatment, but cells
were cultured in the presence of insulin, which strongly
activates the PI3K pathway. Furthermore, cell cultures
were deprived of serum and TSH for only 16 h,
whereas our starvation period is much longer (2–3 d),
and therefore, basal pAkt levels are lower. Thus, the
induction of Akt phosphorylation observed in our ex-
periments is due only to TSH action. This activation
does not appear to be mediated by PKA and cAMP
signaling, because pretreatment with H89 (an inhibitor
of PKA activity) or Rp-cAMP (an analog competitor of
cAMP that inhibits signaling downstream of cAMP,
including PKA) does not affect TSH induction of Akt
phosphorylation. We found that forskolin is also able
to induce PI3K-dependent Akt phosphorylation but to
a much lesser extent than TSH. In view of these re-
sults, we cannot rule out the existence of a cAMP-
PKA/PI3K pathway in PCCl3 cells, as has been dem-
onstrated in FRTL5 cells (56), but it does not seem to
be the only signaling pathway promoting stimulation of
PI3K by TSH. No doubt, both PKA and PI3K are play-
ing crucial roles in the regulation of thyroid cell prolif-
eration and differentiation, and the reported opposite
effects of PKA on PI3K activity reflect the complexity
of the signaling cascades and the processes these
kinases are controlling. Much work needs to be done
to unravel whether this complex regulation is ex-
plained by different PKA and PI3K isoforms. Thus, our
results describe a new signaling pathway leading to
PI3K activation in response to TSH, involving G
dimers and occurring in a cAMP-independent manner.
This new pathway regulates thyroid differentiation and
thus thyroid function.
To further address the mechanism of inhibition of
NIS gene expression by G, we analyzed the levels of
Pax8 and its binding to the rat NIS promoter. Pax8 is
the main transcription factor regulating NIS gene ex-
pression. It has been demonstrated that Pax8 binding
to this region is required for the TSH/cAMP induction
of NIS transcription. Here we show that TSH induction
of Pax8 binding to the NIS promoter increases when
G signaling is inhibited by overexpression of G
scavengers. On the other hand, G sequestration
does not affect the binding of Pax8 induced by fors-
kolin, reflecting the results obtained when promoter
activity was analyzed. The amount of Pax8 bound to
the NIS promoter in cells treated with TSH also in-
creases when PI3K is inhibited by LY294002, indicat-
ing that signals leading to PI3K activation diminish
Pax8 binding activity to the NIS promoter. We can
conclude that the release of G dimers induced by
TSH activates PI3K in PCCl3 cells and down-regulates
NIS transcription by decreasing Pax8 binding to the
NIS promoter.
The mechanism involved in the regulation of Pax8
binding to NIS promoter is still not well defined. Pax8
is a phosphoprotein whose phosphorylation seems to
be not dependent on cAMP pathway activation (57).
However, the Pax8 activation domain is dependent
upon the catalytic subunit of the PKA and it has been
proposed that this dependence involves a hypotheti-
cal adaptor that is targeted by PKA and interacts with
the activating domain of Pax8 (58). Concerning the
regulation of Pax8 binding by other kinases, such as
PI3K, the only data reported so far are the ones de-
scribed here. We think that the situation could be
similar to the one reported for cAMP/PKA, because
Pax8 phosphorylation seems to be independent of
PI3K activation (our unpublished data). In fact, our
preliminary results suggest that the inhibition of Pax8
binding to the NIS promoter by PI3K/Akt is mediated
by the interaction of Pax8 with the transcription factor
FoxO1, a forkhead factor activated by the IGF-I/PI3K/
Akt pathway (59). These preliminary results raise inter-
esting questions regarding the regulation of Pax8 ac-
tivity. Along with this line, we report here that Pax8 is
excluded from the nucleus when G dimers are over-
expressed, and this effect is partly impaired when
PI3K is inhibited. This is an interesting observation that
remains to be studied in detail, although we hypothe-
size that FoxO1 could also be involved, because it has
been described that FoxO1 is excluded from the nu-
cleus after phosphorylation by PI3K (60). The new
pathway described here does not seem to be involved
in the regulation of expression of Tg, another thyroid
differentiation marker. Like NIS expression, Tg gene
expression is stimulated by TSH/cAMP, but contrary
to what happens for NIS, Pax8 is not the main tran-
scription factor regulating the expression of Tg. More-
over, IGF-I differentially regulates TSH-induced Tg (49)
and NIS (33) expression. Thus, it would be expected
that a decrease in Pax8 DNA binding activity and/or
PI3K activation would not affect the expression of the
Tg gene.
In view of the results presented here, we can con-
clude that TSH activates the PI3K/Akt pathway not
only in a cAMP-dependent manner, as was reported
previously (30, 61), but also by a cAMP-independent
mechanism that involves G subunits. We demon-
strate that G subunits induce Akt phosphorylation
and interfere with NIS gene expression induced by
TSH and forskolin. Down-regulation of NIS gene ex-
pression by G dimers occurs at the transcriptional
level, because G dimers reduce the ability of Pax8
to bind the NIS promoter and induce the exclusion of
Pax8 from the nucleus. These results demonstrate a
functional role for G dimers in thyroid cell differen-
tiation, and more studies are needed to clarify the
mechanism underlying the inhibition of Pax8 DNA
binding and its exclusion from the nucleus. On the
other hand, the diversity of signaling pathways acti-
vating PI3K in the thyroid cell (summarized in Fig. 10)
suggests the involvement of different PI3K subtypes.
Future studies will be focused on the identification of
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the PI3K isoforms that mediate cAMP, G, or recep-
tor tyrosine kinase signaling in thyroid cells.
It is well accepted that TSH induces a number of
negative feedback loops (through different pathways)
that counteract its own proliferative actions as a protec-
tive mechanism against tumorigenesis (38, 62). It has
been reported the negative regulation elicited by TSH on
TSHR expression (51). The significance of the dual reg-
ulation of NIS gene transcription by TSH, which at the
same time activates through Gs/cAMP/PKA and re-
presses through G/PI3K/Akt, is an intriguing issue.
The most plausible explanation is that thyroid cells need
to maintain a tight control of NIS protein levels, because
iodide uptake is the limiting step for thyroid hormone
biosynthesis. TSH is the main regulator of this uptake by
a mechanism that induces NIS expression both at the
transcriptional (6) and posttranscriptional levels (34). The
other main regulator of iodide accumulation is the iodide
itself that exerts an autoregulatory mechanism that pro-
tects the thyroid from high doses of iodide (the so called
Wolff-Chaikoff effect) (63). In an analogous way, we in-
terpret the dual opposite actions of TSH (stimulatory
through cAMP and inhibitory through G dimers) as an
autoregulatory system to maintain a constant rate of
iodide entering the cells.
MATERIALS AND METHODS
Materials
hrTSH was kindly provided by Genzyme (Madrid, Spain).
Tissue culture media, bovine TSH, BSA, anti-Flag antibody,
PTX, and bovine insulin were purchased from Sigma Chem-
ical Co. (St. Louis, MO). IGF-I was obtained from Peprotech
(Rocky Hill, NJ). Forskolin, H89, Rp-cAMP, LY294002, wort-
mannin, 3-isobutyl-1-methylxanthine (IBMX), anti-CREB-1,
and anti-pCREB antibodies were purchased from Calbio-
chem (La Jolla, CA). Donor calf serum and DMEM were
obtained from Life Technologies, Inc. (Gaithersburg, MD).
cAMP enzyme immunoassay Biotrak (EIA) System (dual
range) was from Amersham, General Electrics Healthcare
(Buckinghamshire, UK). The dual-luciferase reporter assay
system and the products for the RT-PCR were purchased
from Promega Corp. (Madison, WI). Restriction enzymes
were obtained from Invitrogen (Paisley, UK); streptavidin-
horseradish peroxidase conjugate, anti-Akt1/2, anti-CD8,
anti-Sp1, and anti-actin antibodies, and Luminol detection
reagent were obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Anti-pAkt (pSer472/473/474) was from
Pharmingen (San Diego, CA). Anti-Tg antibody was from
Dako (Glostrup, Denmark), and anti-Pax8 antibody was from
BioPat (Piedimonte Matese, Italy). Vectashield mounting me-
dium containing 4,6-diamidino-2-phenylindole (DAPI) was
from Vector Laboratories, Inc. (Burlingame, CA). Anti-NIS
antibody was a generous gift from Dr. N. Carrasco (Albert
Einstein College of Medicine, Bronx, NY). CTX was kindly
provided by Dr. M. J. Toro (Universidad de Alcala´ de Henares,
Madrid, Spain).
Plasmids
pRL-TK, which contains a cDNA coding for Renilla, was used
to monitor transfection efficiency. The reporter constructs
used were: pNIS-2.8-Luc, which contains a 2.854-bp DNA
fragment of the rat NIS promoter (33), hTGenh/prm-Luc,
which contains the human Tg promoter/enhancer (64), and
3xCRE-Luc, which contains three CREs in tandem (65). N-
terminal FLAG-tagged human G-protein 1 subunit and N-
terminal HA-tagged human G-protein 2 subunit, cloned into
pcDNA3.1, were obtained from the Guthrie cDNA Resource
Center (Sayre, PA). pCISGT-1, an expression vector for the
-subunit of bovine transducin, CD8-ARK, an expression
vector containing the extracellular and transmembrane do-
main of the CD8 lymphocyte-specific receptor and the car-
boxyl-terminal fragment of human ARK1 (35), were kindly
provided by Dr. F. Mayor, and Dr. C. Murga (Centro de
Biologia Molecular, Consejo Superior de Investigaciones
Cientı´ficas, Madrid, Spain). The same vector containing the
extracellular and the transmembrane domain of the CD8 lym-
phocyte-specific receptor was used as the control vector in
transfection experiments.
Cell Culture
PCCl3 cells are a continuous line of thyroid follicular cells
derived from Fischer rats that constitute a model system with
which to study differentiation and growth regulation in a
thyroid epithelial cell setting. These cells express the thyroid-
specific genes Tg, TPO, and NIS as well as the thyroid-
specific transcription factors TTF1, FoxE1, and Pax8 (66).
They were grown in Coon’s modified Ham’s F-12 medium
supplemented with 5% donor calf serum and a six-hormone
mixture [1 nM TSH, 10 g/ml insulin, 10 ng/ml somatostatin,
5 g/ml transferrin, 10 nM hydrocortisone, and 10 ng/ml
glycyl-L-histidyl-L-lysine acetate] (35, 66). The effect of hor-
mones and growth factors was studied by starving near-
confluent cells for TSH and insulin in the presence of 0.2%
BSA (starvation medium, indicated as  in the figures) from
2–6 d.
Ligands were added to the culture medium at the following
final concentrations: 1 nM TSH, 100 ng/ml IGF-I, and 10 M
forskolin (unless otherwise indicated). hrTSH was used at
concentrations ranging from 0.1–1 g/ml. The inhibitors H89,
LY294002, and wortmannin and the cAMP competitor Rp-
Fig. 10. Model Explaining the Diversity of PI3K Activating
Pathways in the Thyroid Cell
Growth factors such as IGF-I activate PI3K through receptor
tyrosine kinases; TSH binds to its GPCR and stimulates PI3K
activity by two mechanisms: one is dependent on cAMP genera-
tion and probably signals to PI3K through cAMP-GEFs and Ras
proteins; the second one involves G subunits that activate PI3K
in a cAMP-independent manner and down-regulate NIS gene ex-
pression by reducing Pax8 binding to the NIS promoter.
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cAMP were added to the cells 1 h before hormone addition at
the concentrations and times indicated in the experiments
described in Results. PTX (100 ng/ml) was added 24 h before
treatment, and CTX was added for 24 h at a final concentra-
tion of 200 ng/ml.
Immunofluorescence Assay
Cells were seeded on coverslips and transfected with the
plasmids indicated in Fig. 9. After a 2-d starvation period,
cells were stimulated with TSH for 24 h. The PI3K inhibitor
LY294002 was added at a final concentration of 10 M, 1 h
before the hormone treatment. The coverslips were washed
three times and fixed in 70% methanol at 20 C for 10 min,
washed again, blocked with PBS containing 5% donor calf
serum and 0.05% Tween 20 for 1 h at room temperature,
incubated with anti-Pax8 and anti-FLAG or anti-CD8 for 1 h
at RT, washed three times in PBS-Tween 20 for 5 min, incu-
bated for 1 h at room temperature with the secondary anti-
bodies Alexa 488 and TexasRed 546, washed three times
with PBS-Tween, and mounted on Vectashield containing
DAPI (Vector). Cells were observed under a confocal micro-
scope using 63 magnification under an oil immersion ob-
jective (Leica Corp., Deerfield, IL). A 0- to 50-m scale is
shown in the first picture of the third column. The quantifica-
tion of the experiments is represented as the percentage of
successfully transfected cells that present a clear (30%)
Pax8 cytoplasmic localization. Five different fields were ran-
domly chosen from each experiment. The data are the
mean  SD of three independent experiments. In all the
immunofluorescence studies, the control of cells transfected
with G or ARK was respectively performed with anti-
FLAG or anti-CD8 antibodies.
cAMP Assays
The Biotrak cAMP competitive enzyme immunoassay system
was used following the manufacturer’s instructions. Briefly,
CD8-ARK- or G1/G2-transfected PCCl3 cells were grown
in p60 plates (6 105 cells), maintained in starvation medium
for 2 d, and then treated with 0.5 mM IBMX to inhibit cAMP
degradation, followed by 1 nM TSH treatment for 1 h. Cells
were then lysed, the lysate was applied to a donkey antirabbit
IgG-precoated microtiter plate, and incubated with anti-
cAMP antiserum for 2 h at 4 C, after which samples were
incubated with a cAMP-peroxidase-conjugated antibody (1 h
at 4 C) and washed four times with washing buffer. The
enzyme substrate was added immediately afterward to all
wells and incubated (1 h at room temperature). Before OD
determination in a plate reader at 450 nm, the reaction was
terminated by adding 1 M H2SO4 to each well. In parallel, a
standard curve was prepared with cAMP concentrations
ranging from 12.5–3200 fmol/well. Each value represents the
mean  SD of three different experiments.
Flow Cytometry Assay
PCCl3 cells were seeded at a density of 6  105 cells per
60-mm-diameter tissue culture dish and maintained in the
presence of a six-hormone mixture including TSH, insulin,
and 5% serum (control) for 3 d or starved from these factors
for 2, 4, or 6 d. After treatment, cells were trypsinized and
collected, washed three times in cold PBS, and fixed with
ethanol at 20 C overnight. After three washes with cold
PBS, cells were stained with propidium iodide (15 g/ml). At
least 10,000 cells were analyzed per sample, and cell cycle
distribution was quantified using a BD Biosciences (San
Jose, CA) fluorescence-activated cell analyzer. Data were
analyzed with Cell Quest Pro software.
Protein Extraction and Western Blot Analysis
Whole-cell extracts were obtained by resuspending the cell
pellet in a buffer containing 50 mM HEPES (pH 7.0), 2 mM
MgCl2, 250 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1%
Nonidet P-40, 1 mM dithiothreitol, 2M Na3VO4, 10 mM NaF, 1
mM phenylmethylsulfonyl fluoride, 10 g/ml pepstatin A, 10
g/ml aprotinin, and 10 g/ml leupeptin. When protein ex-
tracts were used for luciferase assays, cell pellets were re-
suspended in passive lysis buffer from the dual-luciferase
reporter assay system. Protein concentration was deter-
mined according to Bradford (67) with the Bio-Rad Labora-
tories, Inc. (Hercules, CA), protein assay kit. Total cell extract
proteins (30 g) were separated by SDS-PAGE and trans-
ferred to a nitrocellulose membrane (Schleicher & Schuell,
Dassel, Germany). Membranes were blocked in PBS-T buffer
(PBS plus 0.1% Tween 20, pH 7.5) containing 5% nonfat
milk. After incubation with antibodies in PBS-T containing 5%
nonfat milk, membranes were washed four times with PBS-T
buffer and incubated with streptavidin-horseradish peroxi-
dase conjugate, followed by four washes of 10 min each with
PBS-T buffer. Immunoreactive bands were visualized with
the Luminol Western blot detection reagent (Santa Cruz Bio-
technology). Protein expression levels were quantified using
ImageQuant software (Molecular Dynamics, Inc., Sunnyvale,
CA). The protein of interest was quantified and normalized in
all cases to its loading control.
The graphic below each Western blot assay shows the
average of at least three different experiments. Data were
analyzed with GraphPad Prism (Intuitive Software for Sci-
ence, San Diego). Relative protein expression is the mean 
SD. Statistical significance was determined by t test analysis
(two-tailed), and differences were considered significant at
P  0.05.
EMSAs
Nuclear extracts from PCCl3 cells were prepared following
the procedure described by Andrews and Faller (68). Protein
concentration was measured as described above using BSA
as a standard. An oligonucleotide probe corresponding to the
Pax8-binding site in the rat NIS promoter (site PB within the
NUE) (6) was labeled with [32P]ATP by polynucleotide ki-
nase. Nuclear extracts (7 g) from PCCl3 cells transfected
and treated as indicated in the corresponding figures were
incubated with the labeled probe. Binding reactions were
performed in a buffer containing 40 mM HEPES (pH 7.9), 200
mM KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol, 150 ng/l
poly(dI-dC), and 5% Ficoll at room temperature for 30 min.
Binding reactions were preincubated for 15 min on ice with an
excess of cold Pax8 DNA-binding site oligonucleotide or
unrelated DNA for competition experiments. When required,
an anti-Pax8 antibody directed against the Pax8 DNA-
binding site was used. Samples were electrophoresed on
a 5% polyacrylamide gel in 0.5 Tris-borate-EDTA. Gels
were transferred to Whatman 3MM paper, dried, and
autoradiographed.
Transfections
PCCl3 cells were plated at a density of 6  105 cells per
60-mm-diameter tissue culture dish 48 h before transfection.
Transfections were performed by calcium phosphate copre-
cipitation as described previously (69). Twenty-four hours
after transfection, culture medium was changed to starvation
medium, and cells were maintained in this medium for 48–72
h or for 5 d for NIS and Tg detection. After this time, cells were
treated with the different hormones for the times indicated in
each experiment. For NIS, Tg, and CRE promoter activity
analyses, cells were transfected with 5 g pNIS-2.8, 3 g
hTGenh/prm-Luc, or 5 g 3XCRE-Luc. To correct for trans-
fection efficiency, 0.5 g of the Renilla-encoding pRL-TK
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vector was added in all cases. Different amounts of FLAG-
G1, HA-G2, and CD8-ARK, ranging from 1–5 g, were
transfected as indicated. After 48 h, cells were harvested,
lysed, and analyzed for luciferase and Renilla activities. The
promoter activity in cells transfected with the expression
vector was determined as the ratio between luciferase and
Renilla, relative to the ratio obtained in cells transfected with
the corresponding control vector. The results shown are the
average  SD of three different experiments performed in
triplicate, and data were analyzed with GraphPad Prism (In-
tuitive Software for Science, San Diego, CA). Statistical sig-
nificance was determined by t test analysis (two-tailed), and
differences were considered significant at P  0.05.
Western blots were done where indicated to determine the
levels of the transfected expression vectors.
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